Scarica l'app Stockscreener
1.84
6.98%
0.12
Precedente Chiudi:
$1.72
Aprire:
$1.81
Volume 24 ore:
1.17M
Relative Volume:
0.63
Capitalizzazione di mercato:
$271.02M
Reddito:
$72,500
Utile/perdita netta:
$-45.96M
Rapporto P/E:
-2.7003
EPS:
-0.6814
Flusso di cassa netto:
$-44.56M
1 W Prestazione:
+8.24%
1M Prestazione:
-13.21%
6M Prestazione:
+105.61%
1 anno Prestazione:
+125.74%
Intervallo 1D:
$1.78
$1.905
Intervallo di 1 settimana:
$1.675
$1.905
Portata 52W:
$0.779
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.84 | 250.40M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-02-28 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-10-28 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-06 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-04-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-05 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-01-29 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-10 | Iniziato | Credit Suisse | Outperform |
| 2018-07-13 | Iniziato | BMO Capital Markets | Outperform |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-28 | Iniziato | SunTrust | Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Inflarx Nv Borsa (IFRX) Ultime notizie
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey
TradingKey - TradingKey
InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView
InflaRx NV (IFRX) Cash Flow - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et
IFRX Stock Price, Quote & Chart - ChartMill
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss on Stability, Stock EasesEarnings Call Q&A - DonanımHaber
InflaRx NV focus on immune therapies as investors weigh long-term prospects - ad-hoc-news.de
InflaRx N.V. (IFRX) Slips 1.79% as Stock Approaches Key Support LevelETF Premium Discount - DonanımHaber
IFRX Q1 2026 Earnings: Surprise EPS Beat Despite Pre-Revenue StatusCapex Guidance - dars.gov.et
Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
IFRXInflaRx NV Revenue Breakdown - Finviz
Price to book forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos - TipRanks
InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan
InflaRx to explore regulatory path for AAV drugs in Europe - Investing.com
InflaRx to explore regulatory path for AAV drugs in Europe By Investing.com - Investing.com South Africa
InflaRx to Engage EMA on Vilobelimab and Izicopan Development Path in AAV - Quiver Quantitative
InflaRx Assessing Feasibility of Broadened Strategy - One News Page
symbol__ Stock Quote Price and Forecast - CNN
Price to sales forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBITDA forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Price to earnings forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to sales forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Price to book forward of InflaRx N.V. – GETTEX:IF0 - TradingView
Enterprise value to revenue forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
Enterprise value to EBIT forward of InflaRx N.V. – GETTEX:IF0 - TradingView
ETFs Investing in InflaRx N.V. Stocks - TradingView
InflaRx N.V. Actuals & Estimates (HAM:IF0) - TradingView
InflaRx N.V. Actuals & Estimates (GETTEX:IF0) - TradingView
IFRX Forecast — Price Target — Prediction for 2027 - TradingView
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
InflaRx NV (IFRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InflaRx N.V. (IFRX) Holds Near Support as Biotech Sentiment WeighsVolatility Breakout Picks - DonanımHaber
InflaRx NV (IFRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InflaRx NV (IFRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InflaRx StockAnalyst views and trading setup midweek - AD HOC NEWS
InflaRx NV (IFRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IFRX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline, Though Stock DeclinesStrong Earnings Momentum - newsline.com
InflaRx N.V. Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEarnings Growth Forecast - newsline.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock SlipsPost-Announcement Reaction - newsline.com
What Do Analysts Say About InflaRx N.V. (IFRX)? - Insider Monkey
InflaRx N.V. (IFRX) Q1 2026 Earnings: EPS Exceeds Expectations as Drug Development Advances - newsline.com
InflaRx N.V. (IFRX) Q4 2025 Earnings: Narrower-than-Expected Loss but Shares Slide 8%Buyback Announcement Report - dars.gov.et
Inflarx Nv Azioni (IFRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):